nach oben

Erschienen in:

01.01.2018 | Case report

Pembrolizumab

Mild rash, increased liver enzymes and protracted diarrhea: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Auszug

A retrospective study described two patients [ages and sexes not stated], of whom one patient developed protracted diarrhoea and one patient developed mild rash with increased liver enzymes following treatment with pembrolizumab. The patients, who had progressive advanced primary brain tumours, received pembrolizumab every three weeks [routes and doses not stated]. One of the two patients developed a mild rash with increased liver enzymes, while the other patient developed protracted diarrhoea [time to reactions onset and outcomes not stated]. …

Blumenthal DT, et al. Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. Journal of Neuro-Oncology 129: 453-460, No. 3, Sep 2016. Available from: URL: http://doi.org/10.1007/s11060-016-2190-1 - IsraelCrossRefPubMed

Titel: Pembrolizumab
Mild rash, increased liver enzymes and protracted diarrhea: 2 case reports
Publikationsdatum: 01.01.2018
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-018-40819-z

Springer Medizin

Pembrolizumab

Mild rash, increased liver enzymes and protracted diarrhea: 2 case reports

Auszug

Weitere Artikel der Ausgabe 1/2018

Epinephrine/lidocaine

Ombitasvir/paritaprevir/ritonavir

Glucose/sodium-chloride

Nivolumab

Dabigatran etexilate/rivaroxaban

Levonorgestrel

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Epinephrine/lidocaine

Ombitasvir/paritaprevir/ritonavir

Glucose/sodium-chloride

Nivolumab

Dabigatran etexilate/rivaroxaban

Levonorgestrel